StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Aggregate of 18 sell-side ratings as of 2026-05-01. Stonvex does not endorse these ratings.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $39.00 | $34.48 | -11.59% | 0.4M |
| 05-19 | $33.24 | $31.67 | -4.72% | 0.7M |
| 05-20 | $32.19 | $31.13 | -3.29% | 0.4M |
| 05-21 | $30.62 | $30.62 | +0.00% | 0.4M |
| 05-22 | $30.62 | $27.57 | -9.96% | 0.5M |
Next report date, year-over-year trend, and recent quarter history.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Past 1 reported quarters: EPS surprise vs estimate and the day-after-release stock reaction. Past performance does not predict future moves.
Sources: Finnhub earnings calendar + Polygon daily aggregates. Reaction direction can diverge from EPS surprise (guidance, macro, or sector flow can dominate the next-day print).
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Each factor shows STRO's percentile within the scored universe — observational ranking, not a recommendation.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Earnings (▲ beat / ▼ miss) and ex-dividend dates plotted on the price line. Educational — proximity does not establish causation.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q3 2026 (Est.) Expected 2026-08-05 | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|---|
Revenue | $10.41M | $14.52M | $102.48M | $90.84M | $81.14M |
Operating Income | Not available | $-29.66M | $-158.37M | $-120.32M | $-71.86M |
Net Income | Not available | $-38.48M | $-191.09M | $-144.32M | $-11.50M |
EPS (Diluted) | $-3.29 | $-2.94 | $-22.49 | $-1.71 | $-1.04 |
Total Assets | Not available | $241.99M | $173.83M | $209.66M | $262.36M |
Total Liabilities | Not available | $308.88M | $306.28M | $296.93M | $294.47M |
Cash & Equivalents | Not available | $73.68M | $58.13M | $65.93M | $64.03M |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | Not available | Not available |
Shares Outstanding | Not available | 16.57M | 8.58M | 85.10M | 84.72M |
STRO is in the extended universe. We surface dollar-volume + price-change percentiles for every US-listed name, but the full 6-factor DNA breakdown (momentum, news, sentiment, flow, relative strength) is only computed on the curated 1137-name primary list.
DNA analysis is not available for this ticker.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.